Antibody Information

General Information of This Antibody
Antibody ID
ANTI0NCMLP
Antibody Name
NY920-CysMab
Synonyms
NY920-CysMab
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized lgG1-kappa
Antigen Name
CD48 antigen (CD48)
  Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFAMSWVRQAPGKGLEWVSAISGFGGSTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQFWEDQPFYFDYWGQGTLVTVS
S
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
NY920-CysMab-VC-MMAE [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.021 nM
High CD48 expression (CD48 +++)
Method Description
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.

   Click to Show/Hide
In Vitro Model Multiple myeloma KMS-21 cells CVCL_2991
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.021 nM
High CD48 expression (CD48 +++)
Method Description
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.

   Click to Show/Hide
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.022 nM
High CD48 expression (CD48 +++)
Method Description
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.

   Click to Show/Hide
In Vitro Model Plasma cell myeloma, Multiple myeloma KMS-27 cells CVCL_2993
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.07 nM
High CD48 expression (CD48 +++)
Method Description
TheabilityoftheCD48ADCstoinhibitcellproliferationandsurvivalwasassessedusingthePromegaCelliter-Gloproliferationassay.Celllineswereculturedin mediathatisoptimalfortheirgrowthat5%C02,370Cinatissuecultureincubator.Priortoseedingfortheproliferationassaythecellsweresplitatleast2daysbeforetheassaytoensureoptimalgrowthdensity.Onthedayofseedingcellviabilityandcelldensityweredeterminedusingacellcounter (ViCellXRCellViabilityAnalyzerBeckmanCoulter).Cells withhigherthan85%viabilitywereseededinwhiteclearbottom384-wellTCtreatedplatesb (Corningcat.#3765).CellswereseededatadensityofI,000cellsperwellin45pLof standardgrowthmedia.Plateswereincubatedat5%C0 2 ,370Covernightinatissueculture incubator.ThenextdayCD48targetingMMAEADCsandnon-targetingisotypeADCs werepreparedatlOXinstandardgrowthmedia.ThepreparedCD48targetingandisotype matchednon targetingcontrolADCtreatmentswereaddedtothecellsresultinginfinalconcentrationsof0.001- 25nMandafinalvolumeof50pLperwell.Eachdrug concentrationwastestedinquadruplets.

   Click to Show/Hide
In Vitro Model Plasma cell myeloma, Multiple myeloma KMS-20 cells CVCL_2990
References
Ref 1 Anti-cd48 antibody, antibody drug conjugate and its use